These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 10872291)

  • 1. [New trend in type 2 diabetes moves toward short-term insulins! Better metabolic control, less weight gain].
    Renner R
    MMW Fortschr Med; 2000 May; 142(21):30-2. PubMed ID: 10872291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of blood glucose levels in the pathogenesis of (atherosclerotic) macroangiopathy].
    Simon K
    Orv Hetil; 2004 Apr; 145(16):861-6. PubMed ID: 15156691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus.
    Yki-Järvinen H
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S77-81. PubMed ID: 12324990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.
    Schütt M; Kern W; Krause U; Busch P; Dapp A; Grziwotz R; Mayer I; Rosenbauer J; Wagner C; Zimmermann A; Kerner W; Holl RW;
    Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):384-8. PubMed ID: 16915542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term benefits of insulin therapy and glycemic control in overweight and obese adults with type 2 diabetes.
    Caballero AE
    J Diabetes Complications; 2009; 23(2):143-52. PubMed ID: 18413192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G; Kopp HP; Ristic S; Muzyka B; Peter L; Mitteregger G
    Horm Metab Res; 2004 Mar; 36(3):188-93. PubMed ID: 15057674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making the transition from oral to insulin therapy.
    Riddle MC
    Am J Med; 2005 May; 118 Suppl 5A():14S-20S. PubMed ID: 15850549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insulin resistance. Frequently administration errors are the source].
    Rendschmidt T; Lüddeke HJ; Renner R; Hepp KD
    MMW Fortschr Med; 2000 May; 142(21):38-41. PubMed ID: 10872293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lispro mixed insulins in type 2 diabetes. Preventing postprandial insulin rise].
    MMW Fortschr Med; 2000 Jul; 142(28-29):58-9. PubMed ID: 10959169
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
    De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
    J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inadequate blood glucose control with oral antidiabetic drugs. Early conversion to insulin].
    MMW Fortschr Med; 2002 Jul; 144(27-28):61. PubMed ID: 12198890
    [No Abstract]   [Full Text] [Related]  

  • 16. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K; Davies M
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary combined oral antidiabetic therapy in type-2 diabetes mellitus].
    Winkler G; Baranyi E
    Orv Hetil; 2002 Oct; 143(43):2441-7. PubMed ID: 12455146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do more diabetic patients need insulin?
    Page S; Tattersall R
    Practitioner; 1996 Feb; 240(1559):104-8. PubMed ID: 8736198
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin injection--a new technique.
    St James P
    Can Nurse; 1969 Jul; 65(7):32-3. PubMed ID: 5785285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.